Shares of Novartis AG (NYSE:NVS) have earned an average recommendation of “Hold” from the nineteen analysts that are currently covering the company. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $80.42.
Several equities research analysts have commented on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis AG in a research note on Tuesday. Vetr upgraded shares of Novartis AG from a “sell” rating to a “buy” rating and set a $77.19 price target on the stock in a research note on Tuesday, February 7th. Barclays PLC assumed coverage on shares of Novartis AG in a research note on Tuesday, March 7th. They issued an “underweight” rating on the stock. Societe Generale upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and increased their price objective for the company from $73.82 to $74.37 in a report on Tuesday, March 7th. Finally, Deutsche Bank AG reiterated a “neutral” rating on shares of Novartis AG in a report on Monday, January 9th.
ILLEGAL ACTIVITY NOTICE: “Novartis AG (NVS) Given Consensus Rating of “Hold” by Brokerages” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/04/20/novartis-ag-nvs-given-consensus-recommendation-of-hold-by-analysts-updated-updated.html.
Shares of Novartis AG (NYSE:NVS) traded up 1.21% on Friday, reaching $73.62. The company had a trading volume of 3,940,013 shares. The company has a market capitalization of $174.78 billion, a P/E ratio of 26.29 and a beta of 0.73. The company has a 50 day moving average of $74.50 and a 200-day moving average of $73.40. Novartis AG has a 52 week low of $66.93 and a 52 week high of $83.58.
Novartis AG (NYSE:NVS) last announced its quarterly earnings results on Wednesday, January 25th. The company reported $1.12 EPS for the quarter, meeting the consensus estimate of $1.12. Novartis AG had a net margin of 13.80% and a return on equity of 15.37%. The company had revenue of $12.32 billion for the quarter, compared to analyst estimates of $12.44 billion. During the same quarter last year, the business earned $1.14 earnings per share. Novartis AG’s revenue was down 1.6% compared to the same quarter last year. Analysts predict that Novartis AG will post $4.69 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of NVS. Capital Investment Advisors LLC boosted its stake in shares of Novartis AG by 0.9% in the third quarter. Capital Investment Advisors LLC now owns 4,025 shares of the company’s stock worth $318,000 after buying an additional 37 shares during the last quarter. Duncker Streett & Co. Inc. boosted its stake in shares of Novartis AG by 0.5% in the third quarter. Duncker Streett & Co. Inc. now owns 7,950 shares of the company’s stock worth $628,000 after buying an additional 37 shares during the last quarter. CENTRAL TRUST Co boosted its stake in shares of Novartis AG by 0.3% in the third quarter. CENTRAL TRUST Co now owns 12,857 shares of the company’s stock worth $1,016,000 after buying an additional 38 shares during the last quarter. Schulhoff & Co. Inc. boosted its stake in shares of Novartis AG by 0.6% in the third quarter. Schulhoff & Co. Inc. now owns 6,839 shares of the company’s stock worth $540,000 after buying an additional 41 shares during the last quarter. Finally, Genesee Valley Trust Co. boosted its stake in shares of Novartis AG by 1.0% in the third quarter. Genesee Valley Trust Co. now owns 4,928 shares of the company’s stock worth $389,000 after buying an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 9.82% of the company’s stock.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.